A

Addex Therapeutics Ltd (ADXN)

NCM – Real Time Price. Currency in USD

6.70

+0.40 (6.35%)

At close: Mar 27, 2026, 4:00 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Addex Therapeutics Ltd (ADXN)

NCM – Real Time Price. Currency in USD

6.70

+0.40 (6.35%)

At close: Mar 27, 2026, 4:00 PM EDT

07.01.2026

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.

11.12.2025

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C.

04.12.2025

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

04.12.2025

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.

01.12.2025

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 BWT / 10:00 EDT / 07:00 PDT) on December 4, 2025

Videos

No Data

There is no data to display

Press releases

07.01.2026

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253.

11.12.2025

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C.

04.12.2025

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update.

Addex Therapeutics Ltd (ADXN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Addex Therapeutics Ltd (ADXN)

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update

Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

Videos

No Data

Press releases

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.

Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update